Recruiting
Phase 2

Blinatumomab

Sponsor:

West Virginia University

Code:

NCT07222579

Conditions

CD19 Positive

Mixed Phenotype Acute Leukemia (MPAL)

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Subcutaneous Blinatumomab

Study Details

Brief summary:

This is a multicenter, non-randomized, open-label, phase II study evaluating blinatumomab administered subcutaneously in adult subjects with CD19+ MPAL. This trial consists of three cohorts of patients with CD19-positive MPAL, categorized as follows: 1. Cohort A: Newly diagnosed CD19+ MPAL in untreated patients who are either ≥ 75 years of age or have at least one coexisting condition precluding intensive chemotherapy. 2. Cohort B: Patients with CD19+ MPAL who have achieved complete remission (CR, CRh, or CRi) following at least one line of treatment but have detectable measurable residual disease (MRD) at a level of ≥ 0.1%, assessed using an assay with a minimum sensitivity of 0.01%. 3. Cohort C: Patients with CD19+ MPAL with morphologic relapsed or refractory (R/R) disease following at least one prior line of treatment. The Primary Objectives for each cohort are for Cohort A: to evaluate the efficacy of SC-blinatumomab in treatment; for Cohort B: to assess the ability of SC-blinatumomab to achieve MRD-negative CR; for Cohort C: to determine the efficacy of SC-blinatumomab in inducing CR, CRh, or CRi in patients.

At specified time points, subjects will undergo the following procedures: collection of informed consent, medical history, demographics, ECOG performance, and physical exam including vital signs as well as neurological examination including examination of writing ability. Subjects will provide samples for complete blood count with differential and blood chemistry profile, have a bone marrow aspiration and biopsy and lumbar puncture will be performed per protocol or if clinically indicated, and/or ECG, Echocardiography, pulmonary function test will be performed only if medically indicated.

The subcutaneous treatment will be given in both the inpatient and outpatient setting. For an individual subject the length of participation includes up to a 3-week screening period, up to a 13-month treatment period, and a safety follow-up visit (30 days after the last dose of study treatment), and a follow-up period.

Conditions

CD19 Positive

Mixed Phenotype Acute Leukemia (MPAL)

Study ID

NCT07222579

Start date

Jan 15, 2026

Status verified date

Apr, 2026

Completion date

Aug, 2031

Anticipated

Primary completion date

Aug, 2029

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

  • Inclusion Criteria:
  • General Criteria for all three Cohorts

  • Subjects must have histologically or cytologically confirmed MPAL based on 2022 WHO criteria
  • Subjects who have undergone allo-HSCT are eligible if they are ≥ 4 weeks post stem cell infusion, have no evidence of GVHD > Grade 2, and are at least ≥ 1 week off of immunosuppressive therapy. Per FDA recommendation, patients should be off of calcineurin inhibitors (CNIs) for at least 4 weeks before receiving blinatumomab
  • Subjects with a CNS leukemia must be clinically stable (i.e., asymptomatic with no focal neurological signs and symptoms, or signs and symptoms unchanged over 4 weeks with no > grade 2 manifestations) with a flow cytometric clear CSF in the 2 weeks prior to day 1 of SC-blinatumomab administration.
  • Ability to understand and willingness to sign a written informed consent document
  • Agree to comply with the study requirements and agree to come to the clinic/hospital for required study visits
  • Subjects with hematologic malignancies are expected to have hematologic abnormalities at study entry
  • Specific Criteria for Cohort A

o Subjects should be ineligible for available induction therapy either if they are 75 years of age or older or if they have at least one of the following coexisting conditions precluding intensive chemotherapy: a history of CHF for which treatment is warranted or a report of EF ≤50% in the last 12 months, a history of chronic stable angina, a report of DLCO of ≤65% or FEV1 ≤65% in the last 12 months, ECOG performance status 3 or 4, Charlson comorbidity index (CCI) ≥3.
  • Specific Criteria for Cohort B

  • CD19+ MPAL in CR/CRh/CRi after at least one line of treatment with MRD positivity at a level of ≥0.1% using an assay with a minimum sensitivity of 0.01%.
  • ECOG performance status ≤2
  • Subjects must have organ function as below:

  • Direct bilirubin ≤ 2.5 mg/dL
  • AST/ALT/Alkaline phosphatase ≤ 5 X institutional upper limit of normal
  • Serum creatinine ≤ 3 mg/dL
  • Specific Criteria for Cohort C

  • Confirmed R/R CD19+ MPAL
  • Previous cytotoxic chemotherapy (except for hydroxyurea) must have been completed by 5 half-lives of the drug(s) prior to day 1 of SC-blinatumomab. Per FDA recommendation, patients should have recovered to no more than Grade 1 toxicities from prior chemotherapy.
  • ECOG performance status ≤2
  • Subjects must have organ function as below:

  • Direct bilirubin ≤ 2.5 mg/dL
  • AST/ALT/Alkaline phosphatase ≤ 5 X institutional upper limit of normal
  • Serum creatinine ≤ 3 mg/dL
  • Exclusion Criteria:
  • Criteria for all three Cohorts

  • Subjects receiving any other investigational agents, or concurrent chemotherapy, radiation therapy, or immunotherapy for cancer treatment not including corticosteroids or hydroxyurea
  • Active, uncontrolled infection; subjects with infection under active treatment and controlled with antimicrobials are eligible

Study Design

Enrollment

78 participants

Anticipated

Allocation

Non randomized

Intervention Model

Single group

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Blinatumomab in Newly Diagnosed CD19+ MPAL, Age ≥ 75 or Unfit for Intensive Chemotherapy

Cohort A: Evaluate the efficacy of SC-blinatumomab in treating newly diagnosed CD19+ MPAL in patients ≥ 75 years old or those deemed unfit for intensive chemotherapy.

  • Each cycle = 34 days (26-day treatment period + 8-day treatment free interval between day 27 and day 34).
  • Cycle 1 receives treatment daily during the first week and 3 times (TIW) weekly (M/W/F) during weeks 2-4.
  • In subsequent cycles, the treatment will be administered TIW during weeks 1-4.
  • All subjects will be hospitalized for days 1-12 of cycle 1.
  • Other treatment doses will be given as outpatients. Subjects will remain in the outpatient department for 1-6 hours after each dose is given.
  • Treatment will be given with ability to delay cycle initiation based on blood counts or general physical/neurological examination findings per clinical indication and institutional standard practice.

experimental: Blinatumomab use in CD19+ MPAL in first or second CR/CRh/CRi with detectable MRD ≥0.1%

Cohort B: Assess the ability of SC-blinatumomab to achieve MRD-negative CR in patients with CD19+ MPAL in CR/CRh/CRi with persistent MRD positivity (≥ 0.1%) after at least one line of treatment.

  • Each cycle = 34 days (26-day treatment period + 8-day treatment free interval between day 27 and day 34).
  • Cycle 1 receives treatment daily during the first week and 3 times (TIW) weekly (M/W/F) during weeks 2-4.
  • In subsequent cycles, the treatment will be administered TIW during weeks 1-4.
  • All subjects will be hospitalized for days 1-12 of cycle 1.
  • Other treatment doses will be given as outpatients. Subjects will remain in the outpatient department for 1-6 hours after each dose is given.
  • Treatment will be given with ability to delay cycle initiation based on blood counts or general physical/neurological examination findings per clinical indication and institutional standard practice.

experimental: Blinatumomab use in Morphologic R/R CD19+ MPAL

Cohort C: Determine the efficacy of SC-blinatumomab in inducing CR, CRh, or CRi in patients with morphologic relapsed or refractory CD19+ MPAL.

  • Each cycle = 34 days (26-day treatment period + 8-day treatment free interval between day 27 and day 34).
  • Cycle 1 receives treatment daily during the first week and 3 times (TIW) weekly (M/W/F) during weeks 2-4.
  • In subsequent cycles, the treatment will be administered TIW during weeks 1-4.
  • All subjects will be hospitalized for days 1-12 of cycle 1.
  • Other treatment doses will be given as outpatients. Subjects will remain in the outpatient department for 1-6 hours after each dose is given.
  • Treatment will be given with ability to delay cycle initiation based on blood counts or general physical/neurological examination findings per clinical indication and institutional standard practice.

Interventions

Subcutaneous Blinatumomab

Blinatumomab will be administered as a subcutaneous (SC) injection.

Primary outcome measure

  • Cohort A - Overall Survival [ Time Frame: Up to 3 years ]
  • Cohort B - Rate of Complete Remission (CR), Complete Remission with Partial Hematological Recovery (CRh), or Complete Remission with Incomplete Hematological Recovery (CRi) with Minimal Residual Disease (MRD) negativity [ Time Frame: At completion of 2 cycles (each cycle is 34 days) ]
  • Cohort C - Rate of Complete Remission (CR) or Complete Remission with Partial Hematological Recovery (CRh) [ Time Frame: At completion of 2 cycles (each cycle is 34 days) ]

Central Contacts and Locations

Central contacts

Ashkan Emadi, MD

304-293-5949MPALStudyWVUCI@hsc.wvu.edu

Lindsay Carter

304-293-5949MPALStudyWVUCI@hsc.wvu.edu

Locations

West Virginia University Cancer Institute

Recruiting

Morgantown, West Virginia, United States, 26506

Contacts

Ashkan Emadi, MD

304-598-6734ashkan.emadi@hsc.wvu.edu

Lindsay Carter

304-293-0220lindsay.carter@hsc.wvu.edu

Principal Investigator:

Ashkan Emadi, MD

More Information

Sponsor

West Virginia University

Last update posted

Apr 13, 2026

Last verified

Apr, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by West Virginia University on 2026-04-13.